niacinamide has been researched along with Lymph Node Metastasis in 33 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares." | 7.83 | Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. ( Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B, 2016) |
| "A 66-year-old man with malignant melanoma was treated with sorafenib, 2 yen 400 mg per day." | 7.75 | Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. ( Frieling, T; Heise, J; Wassilew, SW, 2009) |
| "Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares." | 3.83 | Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. ( Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B, 2016) |
| "THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC)." | 3.80 | Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. ( Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M, 2014) |
| "A 66-year-old man with malignant melanoma was treated with sorafenib, 2 yen 400 mg per day." | 3.75 | Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. ( Frieling, T; Heise, J; Wassilew, SW, 2009) |
| "The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome." | 2.76 | A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011) |
| "Sorafenib 400 mg was administered orally twice daily continuously." | 2.73 | A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. ( Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W, 2008) |
| "Furthermore, the level of me-NAM in cervical cancer tissues of stage I, II, III, and IV was higher than that of those without lymph node metastasis." | 1.62 | Diagnostic Value of Serum N1-Methylnicotinamide in Cervical Cancer Patients. ( Ji, M; Lin, S; Na, N, 2021) |
| "Prognostic biomarkers for patients with clear cell renal cell carcinoma (ccRCC), particularly those receiving therapy targeting angiogenesis, are not well established." | 1.48 | Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis. ( Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W, 2018) |
| "Long-term stabilization of advanced renal cell carcinoma (RCC) by the sequence of sorafenib monotherapy followed by sunitinib and everolimus treatments in a man with multiple metastases is reported." | 1.37 | Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. ( Beck, J; Bellmunt, J; Escudier, B, 2011) |
| "Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer." | 1.37 | Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. ( Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.06) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 20 (60.61) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, M | 1 |
| Na, N | 1 |
| Lin, S | 1 |
| Knackstedt, TJ | 1 |
| Knackstedt, RW | 1 |
| Djohan, M | 1 |
| Djohan, R | 1 |
| Gastman, BR | 1 |
| Crowe, DR | 1 |
| Giesel, FL | 1 |
| Will, L | 1 |
| Paddubny, K | 1 |
| Kremer, C | 1 |
| Rathke, H | 1 |
| Radtke, JP | 1 |
| Kopka, K | 1 |
| Haufe, S | 1 |
| Haberkorn, U | 1 |
| Kratochwil, C | 1 |
| Chen, X | 1 |
| Liu, L | 1 |
| Wang, J | 1 |
| Lin, Z | 1 |
| Xiong, Y | 1 |
| Qu, Y | 1 |
| Wang, Z | 1 |
| Yang, Y | 1 |
| Guo, J | 1 |
| Xu, J | 1 |
| Cao, YW | 1 |
| Liu, Y | 1 |
| Dong, Z | 1 |
| Guo, L | 1 |
| Kang, EH | 1 |
| Wang, YH | 1 |
| Zhang, W | 1 |
| Niu, HT | 1 |
| Jiang, W | 1 |
| Zeng, ZC | 1 |
| Massicotte, MH | 1 |
| Brassard, M | 1 |
| Claude-Desroches, M | 1 |
| Borget, I | 1 |
| Bonichon, F | 1 |
| Giraudet, AL | 1 |
| Do Cao, C | 1 |
| Chougnet, CN | 1 |
| Leboulleux, S | 1 |
| Baudin, E | 1 |
| Schlumberger, M | 1 |
| de la Fouchardière, C | 1 |
| Niederkorn, A | 1 |
| Wackernagel, W | 1 |
| Artl, M | 1 |
| Schwantzer, G | 1 |
| Aigner, B | 1 |
| Richtig, E | 1 |
| Sinn, DH | 1 |
| Cho, JY | 1 |
| Gwak, GY | 1 |
| Paik, YH | 1 |
| Choi, MS | 1 |
| Lee, JH | 1 |
| Koh, KC | 1 |
| Paik, SW | 1 |
| Yoo, BC | 1 |
| Buchler, T | 1 |
| Bortlicek, Z | 1 |
| Poprach, A | 1 |
| Pavlik, T | 1 |
| Veskrnova, V | 1 |
| Honzirkova, M | 1 |
| Zemanova, M | 1 |
| Fiala, O | 1 |
| Kubackova, K | 1 |
| Slaby, O | 1 |
| Svoboda, M | 1 |
| Vyzula, R | 1 |
| Dusek, L | 1 |
| Melichar, B | 1 |
| Lorenzin, D | 1 |
| Pravisani, R | 1 |
| Leo, CA | 1 |
| Bugiantella, W | 1 |
| Soardo, G | 1 |
| Carnelutti, A | 1 |
| Umberto, B | 1 |
| Risaliti, A | 1 |
| Ikegami, T | 1 |
| Yoshizumi, T | 1 |
| Kawasaki, J | 1 |
| Nagatsu, A | 1 |
| Uchiyama, H | 1 |
| Harada, N | 1 |
| Harimoto, N | 1 |
| Itoh, S | 1 |
| Motomura, T | 1 |
| Soejima, Y | 1 |
| Maehara, Y | 1 |
| Ansari, J | 1 |
| Fatima, A | 1 |
| Chaudhri, S | 1 |
| Bhatt, RI | 1 |
| Wallace, M | 1 |
| James, ND | 1 |
| Desar, IM | 1 |
| Mulder, SF | 1 |
| Stillebroer, AB | 1 |
| van Spronsen, DJ | 1 |
| van der Graaf, WT | 1 |
| Mulders, PF | 1 |
| van Herpen, CM | 1 |
| Frieling, T | 1 |
| Heise, J | 1 |
| Wassilew, SW | 1 |
| Spector, E | 1 |
| Franklin, MJ | 1 |
| Truskinovsky, AM | 1 |
| Dudek, AZ | 1 |
| Paulino, AC | 1 |
| Pappo, A | 1 |
| Beck, J | 1 |
| Bellmunt, J | 1 |
| Escudier, B | 1 |
| Hou, MM | 1 |
| Hsieh, JJ | 1 |
| Chang, NJ | 1 |
| Huang, HY | 1 |
| Wang, HM | 1 |
| Chuang, CK | 1 |
| Hsu, T | 1 |
| Chang, JW | 1 |
| Machens, A | 1 |
| Dralle, H | 1 |
| Tagawa, ST | 1 |
| Milowsky, MI | 1 |
| Jeske, S | 1 |
| Mazumdar, M | 1 |
| Kung, S | 1 |
| Sung, M | 1 |
| Lehrer, D | 1 |
| Matulich, D | 1 |
| Selzer, J | 1 |
| Wright, JJ | 1 |
| Nanus, DM | 1 |
| Denoyer, D | 1 |
| Potdevin, T | 1 |
| Roselt, P | 1 |
| Neels, OC | 1 |
| Kirby, L | 1 |
| Greguric, I | 1 |
| Katsifis, A | 1 |
| Dorow, DS | 1 |
| Hicks, RJ | 1 |
| Grundbichler, M | 1 |
| Mlineritsch, B | 1 |
| Ressler, S | 1 |
| Moik, M | 1 |
| Kappacher, A | 1 |
| Rosenlechner, S | 1 |
| Greil, R | 1 |
| Cabrejas Gómez, Mdel C | 1 |
| Aguillo Gutiérrez, E | 1 |
| Altemir Trallero, J | 1 |
| Ocón Bretón, J | 1 |
| Lázaro Sierra, J | 1 |
| García-Martín, A | 1 |
| López-Ibarra Lozano, PJ | 1 |
| Triviño-Ibáñez, EM | 1 |
| Escobar-Jiménez, F | 1 |
| Kang, HC | 1 |
| Tan, KS | 1 |
| Keefe, SM | 1 |
| Heitjan, DF | 1 |
| Siegelman, ES | 1 |
| Flaherty, KT | 1 |
| O'Dwyer, PJ | 1 |
| Rosen, MA | 1 |
| Gridelli, C | 1 |
| Rossi, A | 1 |
| Mongillo, F | 1 |
| Bareschino, M | 1 |
| Maione, P | 1 |
| Ciardiello, F | 1 |
| Chi, KN | 1 |
| Ellard, SL | 1 |
| Hotte, SJ | 1 |
| Czaykowski, P | 1 |
| Moore, M | 1 |
| Ruether, JD | 1 |
| Schell, AJ | 1 |
| Taylor, S | 1 |
| Hansen, C | 1 |
| Gauthier, I | 1 |
| Walsh, W | 1 |
| Seymour, L | 1 |
| Moncrieff, M | 1 |
| Shannon, K | 1 |
| Hong, A | 1 |
| Hersey, P | 1 |
| Thompson, J | 1 |
| Shuch, B | 1 |
| Riggs, SB | 1 |
| LaRochelle, JC | 1 |
| Kabbinavar, FF | 1 |
| Avakian, R | 1 |
| Pantuck, AJ | 1 |
| Patard, JJ | 1 |
| Belldegrun, AS | 1 |
| Kaanders, JH | 1 |
| Pop, LA | 1 |
| Marres, HA | 1 |
| Liefers, J | 1 |
| van den Hoogen, FJ | 1 |
| van Daal, WA | 1 |
| van der Kogel, AJ | 1 |
| Duschet, P | 1 |
| Schwarz, T | 1 |
| Gschnait, F | 1 |
| Lorenz, W | 1 |
| Halbach, S | 1 |
| Gerant, M | 1 |
| Werle, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer[NCT00093457] | Phase 2 | 28 participants (Actual) | Interventional | 2004-08-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Lymph Node Metastasis
| Article | Year |
|---|---|
New Developments in the Management of Cutaneous Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoprevention; Chemotherapy, Adjuvant; Humans; Ly | 2021 |
4 trials available for niacinamide and Lymph Node Metastasis
| Article | Year |
|---|---|
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin | 2011 |
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; C | 2013 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell L | 2007 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antin | 2008 |
28 other studies available for niacinamide and Lymph Node Metastasis
| Article | Year |
|---|---|
Diagnostic Value of Serum N1-Methylnicotinamide in Cervical Cancer Patients.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Female; Humans; Lymphatic Metastasis; Niacinamide; Prognosis; | 2021 |
[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.
Topics: Arthroplasty; Fluorine Radioisotopes; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local | 2018 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney N | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Stu | 2018 |
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembo | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; | 2014 |
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Met | 2014 |
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Ne | 2015 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Huma | 2016 |
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Fema | 2016 |
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studie | 2017 |
Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphatic | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidn | 2009 |
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhe | 2009 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; | 2010 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Mod | 2009 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2011 |
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free | 2010 |
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Ca | 2010 |
Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration.
Topics: Animals; Fluorine Radioisotopes; Lymphatic Metastasis; Melanins; Melanoma; Mice; Mice, Inbred C57BL; | 2011 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2011 |
[Long-standing differentiated thyroid carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillar | 2012 |
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
Topics: Carcinoma, Neuroendocrine; Humans; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea | 2013 |
Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Lower Extremity; Lymphatic Metastas | 2008 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kid | 2008 |
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Topics: Actuarial Analysis; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over | 1998 |
Bullous pemphigoid after radiation therapy.
Topics: Aged; Diagnosis, Differential; Humans; Lymecycline; Lymphatic Metastasis; Male; Niacinamide; Pemphig | 1988 |
Specific histidine decarboxylases in the gastric mucosa of man and other mammals. Determination, location and properties.
Topics: Adenocarcinoma; Animals; Benzene; Carboxy-Lyases; Cats; Cattle; Chlorpromazine; Chromatography, Gel; | 1969 |